替考拉宁经验性治疗中粒细胞缺乏并发感染的疗效分析  

Effect of Teicoplanin to Cure Neutropenic Patients with Infection

作　　者：刘竞[1] 李昕[1] 蒋铁斌[1] 肖广芬[1] 王二华[1] 

机构地区：[1]中南大学湘雅三医院血液科,湖南长沙410013

出　　处：《中华医院感染学杂志》2009年第22期3102-3104,共3页Chinese Journal of Nosocomiology

摘　　要：目的评价替考拉宁经验性治疗中性粒细胞缺乏并发感染患者的疗效及安全性。方法对64例血液病房粒细胞缺乏症并发热患者给予替考拉宁经验性治疗后,评价其临床疗效及安全性。结果在可评价的60例患者中治疗有效53例,有效率为88.3%;不良反应发生率仅为4.7%,为轻度、可逆的不良反应,患者耐受性好。结论替考拉宁是一种高效、低毒、作用迅速的抗菌药物,是血液病房粒细胞缺乏症患者发热时经验性治疗的理想药物。OBJECTIVE To investigate the effect and safety of teicoplanin to cure the neutropenic patients with infection. METHODS The 64 neutropenic patients with fever were treated with teicoplanin for empirical therapy, and then its effect and safety were evaluated. RESULTS Teicoplanin was effective in 53 patients, its effective rate was 88.3 %, the adverse event rate was only 4.7 %, and the adverse reactions were slight and reversible and it was well tolerant to patients. CONCLUSIONS Teicopianin is one of the antibiotic agents with high performance, low toxicity and fast effect, which is an ideal agent for empirical therapy for neutropenic patients with fever in hematology units.

关 键 词：血液病房 粒细胞缺乏症 替考拉宁 发热 

分 类 号：R978.1[医药卫生—药品]